Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality
Science Advances · 29.03.2024 · 10 (13)
DOI: 10.1126/sciadv.adk8264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 29.03.2024. Verfasst von Feng Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Chin…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Although CRISPR-mediated genome editing holds promise for cancer therapy, inadequate tumor targeting and potential off-target side effects hamper its outcomes. In this study, we present a strategy using cryo-shocked lung tumor cells as a CRISPR-Cas9 delivery system for cyclin-dependent kinase 4 ( CDK4 ) gene editing, which initiates synthetic lethal in KRAS-mutant non–small cell lung cancer (NSCLC). By rapidly liquid nitrogen shocking, we effectively eliminate the pathogenicity of tumor cells while preserving their structure and surface receptor activity. This delivery system enables the loaded CRISPR-Cas9 to efficiently target to lung through the capture in pulmonary capillaries and interactions with endothelial cells. In a NSCLC-bearing mouse model, the drug accumulation is increased nearly fourfold in lung, and intratumoral CDK4 expression is substantially down-regulated compared to CRISPR-Cas9 lipofectamine nanoparticles administration. Furthermore, CRISPR-Cas9 editing–mediated CDK4 ablation triggers synthetic lethal in KRAS-mutant NSCLC and prolongs the survival of mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Liangzhu Laboratory, Zhejiang University, Hangzhou 311121, China.
- Jinhua Institute of Zhejiang University, Jinhua 321299, China.
- Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.
ORCID-Profile: Feng Liu, Minhang Xin, Wentao Zhang, Ziyan Liao, Tao Sheng, Jiaqi Shi, Kaixin He, Zhen Gu, Hongjun Li
Zitieren
APA
Liu, F., Xin, M., Feng, H., Zhang, W., Liao, Z., Sheng, T., Wen, P., Wu, Q., Liang, T., Shi, J., Zhou, R., He, K., Gu, Z., & Li, H. (2024). Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality. Science Advances, 10(13). https://doi.org/10.1126/sciadv.adk8264
Vancouver
Liu F, Xin M, Feng H, Zhang W, Liao Z, Sheng T, et al. Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality. Science Advances. 2024;10(13). doi:10.1126/sciadv.adk8264
BibTeX
@article{Liu2024,
author = {Liu, Feng and Xin, Minhang and Feng, Huiheng and Zhang, Wentao and Liao, Ziyan and Sheng, Tao and Wen, Ping and Wu, Qing and Liang, Tingxizi and Shi, Jiaqi and Zhou, Ruyi and He, Kaixin and Gu, Zhen and Li, Hongjun},
title = {Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {13},
doi = {10.1126/sciadv.adk8264}
}
EUVIMED